Breaking News Instant updates and real-time market news.

KPTI

Karyopharm

$7.80

-0.17 (-2.13%)

09:06
07/11/19
07/11
09:06
07/11/19
09:06

Karyopharm enters collaboration with Ivy Brain Tumor Center

The Ivy Brain Tumor Center at the Barrow Neurological Institute has announced a partnership with Karyopharm Therapeutics to accelerate the treatment of brain cancer. The Ivy Brain Tumor Center will employ Karyopharm's oral Selective Inhibitor of Nuclear Export, or SINE, compound, selinexor, in combination with other new-in-class drugs, as a dual-drug experimental therapy for adult glioblastoma. "This academic-private partnership will begin with a preclinical study targeting the protein XP01 in glioblastoma patients and testing several new drug cocktails involving selinexor. Based on detailed pharmacodynamic and pharmacokinetic analyses, the lead drug cocktail will then be pursued as a combined-drug trial within the Ivy Brain Tumor Center's Phase 0 clinical trial portfolio. This unique trial format will enable researchers to understand if the experimental therapy is impacting an individual patient's brain tumor in as little as seven days, therefore saving valuable patient time."

KPTI Karyopharm
$7.80

-0.17 (-2.13%)

03/15/19
WEDB
03/15/19
NO CHANGE
WEDB
Wedbush views Karyopharm 's PDUFA date extension as a positive
Wedbush analyst David Nierengarten maintained an Outperform rating and $6 price target on Karyopharm. In a note titled "FDA Extends PDUFA by Three Months," he said he is inclined to view the extension as a positive for the company "given the negative sentiment on the name and general belief that an April 6, 2019 approval was unlikely."
06/14/19
HCWC
06/14/19
NO CHANGE
Target $29
HCWC
Buy
Karyopharm EHA Phase 1b/2 combination data 'encouraging,' says H.C. Wainwright
H.C. Wainwright analyst Edward White maintained a Buy rating and $29 price target on Karyopharm, saying the company presented "encouraging" early Phase 1b/2 selinexor combination data from the STOMP trial in relapsed or refractory multiple myeloma patients at the European Hematological Association 2019 Annual Meeting. In a research note to investors, White says the updated selinexor with Darzalex data "continues to look good," with efficacy results showing an overall response rate of 73% in Darzalex naive patients versus the EHA abstract data published last month with an ORR of 77%. Looking ahead, White projects revenues of $189M and $241M for selinexor in penta-refractory multiple myeloma and DLBCL, respectively, in 2026. For selinexor in combination multiple myeloma treatment, he forecasts revenues of $332M in 2026, and for selinexor in solid tumors he sees revenues of $241M in 2026.
07/05/19
HCWC
07/05/19
NO CHANGE
Target $32
HCWC
Buy
Karyopharm approval label for Xpovio 'compelling,' says H.C. Wainwright
Karyopharm Therapeutics on Wednesday, three days before the action date date, announced that the FDA granted accelerated approval for Xpovio n relapsed or refractory multiple myeloma patients who have received at least four prior therapies and whose disease was refractory after at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody, H.C. Wainwright analyst Edward White tells investors in a research note. Further, there is not a black box warning or contraindications in the Xpovio label, adds the analyst. He finds the label "compelling and inline with expectations." White estimates Xpovio in the penta-refractory setting will have sales of $5.5less than this year rising to $123.8M in 2026. He keeps a Buy rating on Karyopharm Therapeutics with a $32 price target.
07/05/19
WEDB
07/05/19
NO CHANGE
Target $11
WEDB
Outperform
Wedbush boosts Karyopharm target to $11 from $6 on Xpovio approval
Wedbush analyst David Nierengarten raised his price target for Karyopharm Therapeutics to $11 from $6 after the FDA on Wednesday approved selinexor, now branded as Xpovio, in combination with dexamethasone for the treatment of multiple myeloma in patients who have received at least four prior therapies. The stock closed Wednesday up 36% to $8.90. The label has no black box warnings or contraindications, but does include extensive safety monitoring guidelines and recommendations, Nierengarten tells investors in a research note. Karyopharm has priced Xpovio at $22,000 per month, which comes in higher than expected but is "not unreasonable" in comparison to other FDA-approved multiple myeloma drugs, contends the analyst. He projects sales of $9.1M in fiscal 2019, with peak sales potential approaching $300M. Nierengarten keeps an Outperform rating on Karyopharm Therapeutics.

TODAY'S FREE FLY STORIES

LEVI

Levi Strauss

$19.81

-0.3 (-1.49%)

, RL

Ralph Lauren

$115.16

2.555 (2.27%)

05:11
07/17/19
07/17
05:11
07/17/19
05:11
Downgrade
Levi Strauss downgraded to Sell from Neutral at Goldman Sachs »

Goldman Sachs analyst…

LEVI

Levi Strauss

$19.81

-0.3 (-1.49%)

RL

Ralph Lauren

$115.16

2.555 (2.27%)

PVH

PVH Corp.

$92.50

2.08 (2.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 01

    Aug

  • 19

    Sep

  • 19

    Sep

CRZO

Carrizo Oil & Gas

$11.21

0.5 (4.67%)

05:11
07/17/19
07/17
05:11
07/17/19
05:11
Downgrade
Carrizo Oil & Gas rating change  »

Carrizo Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RL

Ralph Lauren

$115.16

2.555 (2.27%)

05:08
07/17/19
07/17
05:08
07/17/19
05:08
Downgrade
Ralph Lauren rating change  »

Ralph Lauren downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 01

    Aug

  • 19

    Sep

PVH

PVH Corp.

$92.50

2.08 (2.30%)

05:06
07/17/19
07/17
05:06
07/17/19
05:06
Downgrade
PVH Corp. rating change  »

PVH Corp. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

PVH

PVH Corp.

$92.50

2.08 (2.30%)

05:06
07/17/19
07/17
05:06
07/17/19
05:06
Downgrade
PVH Corp. rating change  »

PVH Corp. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

SHLX

Shell Midstream

$21.52

0.32 (1.51%)

05:02
07/17/19
07/17
05:02
07/17/19
05:02
Downgrade
Shell Midstream rating change  »

Shell Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSY

Hershey

$140.43

2.02 (1.46%)

05:00
07/17/19
07/17
05:00
07/17/19
05:00
Upgrade
Hershey rating change  »

Hershey upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

SGEN

Seattle Genetics

$63.12

-0.87 (-1.36%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Upgrade
Seattle Genetics rating change  »

Seattle Genetics upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

04:55
07/17/19
07/17
04:55
07/17/19
04:55
General news
Breaking General news story  »

Week of 7/12 MBA Mortgage…

KSHB

KushCo Holdings

$0.00

(0.00%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
KushCo Holdings management to meet with Compass Point »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

TELL

Tellurian

$7.68

-0.1 (-1.29%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Tellurian management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

CRD.B

Crawford & Company

$9.34

-0.13 (-1.37%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Crawford & Company management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

DOVA

Dova Pharmaceuticals

$16.07

(0.00%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Dova Pharmaceuticals management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Credit Suisse energy analysts to hold an analyst/industry conference call »

Analysts provide a 2Q…

PANW

Palo Alto Networks

$219.83

0.41 (0.19%)

, FTNT

Fortinet

$84.79

-0.19 (-0.22%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
FBN Securities Tech/Internet analyst to hold a group luncheon »

Analyst Seyrafi holds a…

PANW

Palo Alto Networks

$219.83

0.41 (0.19%)

FTNT

Fortinet

$84.79

-0.19 (-0.22%)

PFPT

Proofpoint

$126.33

0.61 (0.49%)

CHKP

Check Point

$116.24

-1.37 (-1.16%)

SAIL

SailPoint

$20.12

-0.27 (-1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 24

    Jul

  • 25

    Jul

  • 01

    Aug

  • 06

    Aug

  • 21

    Aug

  • 21

    Aug

  • 13

    Nov

OVID

Ovid Therapeutics

$2.39

-0.19 (-7.36%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Ovid Therapeutics management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

CLNE

Clean Energy

$2.75

-0.01 (-0.36%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Clean Energy management to meet with Craig-Hallum »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 24

    Jul

  • 08

    Aug

VFF

Village Farms

$9.29

-0.125 (-1.33%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Village Farms management to meet with Roth Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

CASY

Casey's General Stores

$160.35

0.98 (0.61%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Casey's General Stores management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 13

    Nov

CTSO

CytoSorbents

$7.19

0.14 (1.99%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
CytoSorbents management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Credit Suisse financial analysts to hold an analyst/industry conference call »

Analysts provide a market…

04:55
07/17/19
07/17
04:55
07/17/19
04:55
General news
Breaking General news story  »

Beige Book to be released…

CDTX

Cidara Therapeutics

$1.60

-0.01 (-0.62%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Cidara Therapeutics management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

GMRE

Global Medical REIT

$10.66

-0.01 (-0.09%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Global Medical REIT management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 08

    Aug

ULTA

Ulta Beauty

$360.68

4.97 (1.40%)

04:55
07/17/19
07/17
04:55
07/17/19
04:55
Conference/Events
Ulta Beauty management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 29

    Aug

  • 25

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.